BillionToOne, Inc.
BLLNBillionToOne is a molecular diagnostics company that utilizes a proprietary single-molecule next-generation sequencing (smNGS) platform to quantify genetic targets with extreme precision.
Earnings
Next report
Oct 6, 2026 (in 2 months)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
BillionToOne is a molecular diagnostics company that utilizes a proprietary single-molecule next-generation sequencing (smNGS) platform to quantify genetic targets with extreme precision. The company leverages its patented Quantitative Counting Templates (QCTs) to overcome technical noise in cell-free DNA analysis, enabling high-sensitivity liquid biopsies. Its core value proposition lies in providing actionable clinical insights from simple blood draws for prenatal care and oncology.
BillionToOne is a leader in the NIPT market for recessive conditions and a high-growth challenger in the oncology liquid biopsy space through its unique single-molecule quantification technology.
FAQ
- What is BillionToOne, Inc.'s market cap?
- BillionToOne, Inc. (BLLN) has a market capitalization of $6.5B and trades on NASDAQ.
- What is BillionToOne, Inc.'s revenue and profitability?
- BillionToOne, Inc. generated $397.4M in trailing twelve-month revenue with net income of $37.7M, representing a net margin of 9.5%. Gross margin stands at 71.3%, with free cash flow of $33.2M. These figures are based on the Q2 2026 filing.
- Who are BillionToOne, Inc.'s competitors?
- BillionToOne, Inc.'s key competitors include Natera, Inc., Guardant Health, Inc., Illumina, Inc., and others. These companies compete in similar markets and product categories.
- Where is BillionToOne, Inc. headquartered?
- BillionToOne, Inc. is headquartered in United States of America. It has been publicly traded since 2025.
